fore, "Study #01" ran until the discontinuation and "Study #02" after the resumption.
The exclusion criteria were: (1) ≥75 years old in Study #02 (no upper limit for #01); (2) >100 kg of body weight in Study #02 (no upper limit for #01); (3) scheduled for primary stent placement, directional coronary atherectomy or rotablator; (4) history of thrombocytopenia; (5) bleeding symptoms or bleeding diathesis; (6) undergone surgery in the previous 6 weeks; (7) cerebrovascular disorder or a history of such in the previous 2 years; (8) ≥50% stenosis in the left main trunk of the coronary artery; (9) 3-vessel disease; (10) uncontrollable hypertension and pulmonary hypertension; and (11) cardiogenic shock requiring cardiopulmonary resuscitation.
The study was approved by the institutional review board at each study site and written informed consent was given by either the patient or a representative before starting the protocol.
Study Design
After initial coronary angiography had identified the culprit lesion, enrolled subjects were randomly assigned into 3 groups according to the dosage of abciximab: the low-dose group (L group) received an intravenous bolus injection of 0.20 mg/kg followed by 12-h continuous intravenous drip infusion of 10 μg/min in Study #01 or 0.125 μg · kg -1 · min -1 in Study #02; the high-dose group (H group) received an intravenous bolus injection of 0.25 mg/kg followed by 12-h continuous intravenous drip infusion using the same dose as in the L group; placebo group (P group) received bolus injection and 12-h continuous drip infusion of the placebo. Coronary angiography was performed 10 min after the bolus injection, before starting the PCI procedure.
Heparin (initial dose: 100 units/kg in Study #01; 70 units/kg in Study #02) and aspirin (≤162 mg/day) were used concomitantly with abciximab, but the following drugs was prohibited during the 6 months from the start of the investigation: thrombolytic drugs, antiplatelet drugs other than aspirin (ticlopidine was permitted in bailout stent placement cases), anticoagulant drugs other than heparin, PGE1 and its derivatives, dextran, and low-molecular-weight dextran.
PCI Procedure and Criteria for the Use of Bailout Stent
PCI (balloon angioplasty) was performed by the standard procedure of each institution. Bailout stenting was permitted if (1) there was markedly delayed contrast flow, defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade ≤2, 14 or (2) a major morphological problem, such as dissection, occurred.
Efficacy Endpoints
The primary efficacy endpoint was the incidence of major coronary events within 30 days after randomization. Major coronary events were defined as death, MI and/or urgent revascularization for recurrence of ischemia. The secondary endpoint was the incidence of major coronary events during the 6 months post-treatment. MI as a coronary event was defined as follows.
(1) MI during the index hospitalization was defined separately according to the initial presentation and duration from the onset of chest pain. (A) In a patient enrolled in the setting of acute MI, MI within 24 h was adjudicated when presenting with subjective symptoms such as chest pain and ≥0.1 mV increase in the ST-segment elevation in ≥2 leads, lasting for ≥30 min. (B) MI after 24 h in patients enrolled in the setting of acute MI and MI in patients enrolled in the setting of UA were regarded as being present when at least 1 of the following was documented: (i) creatine kinase MB isoenzyme (CK-MB) or creatine kinase (CK) value increased by ≥50% compared with the closest trough and peaking at ≥3-fold the upper limit of normal. In cases that did not have a trough, the baseline values are regarded as such; (ii) Qwave newly detected in leads at ≥2 sites, with a width ≥0.04 s, and/or depth ≥25% of the R-wave.
(2) MI after hospital discharge was adjudicated when at least 1 of the following occurred: (i) CK-MB or CK value ≥ twice the upper limit of normal; (ii) new Q-wave with a width ≥0.04 s, and/or depth ≥25% of the R-wave in ≥2 leads.
Secondary Endpoints With Image Analysis
Efficacy was also assessed by secondary endpoints with image analysis (based on quantitative coronary angiography, QCA). Participation was not mandatory. Image analysis was performed at the core image analysis laboratory and assessed by the Efficacy Review Committee to maintain consistency in both the evaluation and accuracy of measurement. Restenosis was classified as ≥50% diameter stenosis at the treated site 6 months post-PCI.
Based on the angiographic findings, the efficacy for prevention of thrombus formation was evaluated from 1 to 4, as described below. Intracoronary thrombus was defined as an irregular filling defect, outlined and/or stained by contrast medium and in the absence of calcification within the filling defect, or by the presence of a mobile irregular filling defect.
1. Very effective: (i) improvement in blood flow by ≥2 TIMI grades in subjects with TIMI grade 0 or 1 flow or (ii) complete disappearance of an apparent thrombus in subjects with TIMI grade 2 or 3 flow. 2. Effective: (i) improvement in blood flow by 1 TIMI grade in subjects with TIMI grade 0-2 flow or (ii) reduction in the size of an apparent thrombus in subjects with TIMI grade 3 flow, or (iii) improvement (≥10% decrease) in % diameter stenosis by QCA in subjects with no change in TIMI grade.
3. Ineffective: (i) no change in blood flow in subjects with TIMI grade 0-3 flow or (ii) no change in the size of an apparent thrombus in subjects with TIMI grade 0-3 flow, or no improvement in blood flow in subjects with TIMI grade 0-3 flow without an apparent thrombus; (iii) aggravation (≥10% increase) of % diameter stenosis by QCA in subjects with no change in TIMI grade. 4. Aggravated: (i) decrease in blood flow in subjects who had TIMI grade 0-3 flow, or (ii) enlargement of an apparent thrombus in subjects with TIMI grade 0-3 flow.
Safety Endpoints
To evaluate safety, bleeding symptoms and thrombocytopenia were assessed within 6 months in Study #01 and within 30 days in Study #02. The severity of bleeding events was judged according to the TIMI bleeding criteria. 15 Platelet count was measured before the investigational treatment as baseline and at 2-3 h, 8-12 h, 24 h, 2 weeks, 30 days, and 6 months after the start of the investigational treatment. Thrombocytopenia was defined as platelet count <100,000/mm 3 and a decrease by ≥25% from the baseline.
Statistical Analysis
All significance levels were 2-sided and set at 5%. The combined results were used in the efficacy analysis of post-PCI coronary events. Depending on the characteristics of the background factors, the chi-square test (nominal scale), Mantel test (ordered scale) or Kruskal-Wallis test (continuous scale) was used. The primary endpoint was analyzed as a time-to-event variable, and the cumulative incidence rate was determined by the Kaplan-Meier method. Comparisons of incidence among the groups were performed using the log-rank test, which was used for the main analysis. Separate results from Studies #01 and #02 were used for the safety analysis.
Target Sample Size In the EPIC trial, 8 the incidence of postoperative major coronary events within 30 days after PCI was 13.1% in UA patients receiving placebo (n=153), 3.8% in UA patients receiving abciximab continuous drip infusion (n=156), 26.1% in acute MI patients receiving placebo (n=23), and 4.5% in acute MI patients receiving abciximab continuous drip infusion (n=22). Although it was expected that drug efficacy would be more clearly observed in patients with acute MI, the data obtained from the UA patients were used to determine the target sample size for the present study in order to increase the power of statistical analysis. Based on the EPIC data, the expected incidence of postoperative major coronary events in the P group was 15%, and that in the H group was 7.5% (ie, 50% less than that in the P group). When the incidence was compared between the P and H groups, assuming scores (contrast) of −1, 0, and 1 for the P, L, and H groups, respectively, it was determined that a sample size of 300 in each group provided a statistical power of 79.5% at α=0.05 (2-sided), based on the binomial distribution of difference in the incidence.
Results

Study Population
From May to November 1997, 223 subjects were enrolled in Study #01, and from October 1998 to April 2000, 750 subjects were enrolled in Study #02 from 89 study sites (Appendix 1). Of the 973 enrolled subjects, 961 received the investigational drug and were used for safety endpoint analysis. The flowchart of the study population with the reasons for exclusion is shown in Fig 1. Data from 938 subjects (303 in the P group, 314 in the L group, and 321 in the H group) were used for the efficacy analysis. The image analysis subset comprised 851 subjects, and 825 cases of thrombi were evaluated at the coronary angiogram image analysis laboratory. The baseline characteristics of study population are shown in Table 1 . There was no significant difference among the groups in their baseline characteristics.
Efficacy Endpoint
The cumulative incidence rates of post-PCI coronary events during 30 days were 3.6% in the P group, 1.6% in the L group, and 4.1% in the H group, with no significant difference between the P and L groups (P=0.104) or between the P and H groups (P=0.772; Table 2 ). The Kaplan-Meier plot of the 30-day cumulative incidence rates is shown in Fig 2. The cumulative incidence rates of post-PCI coronary events during 6 months were 14.1% in the P group, 15.0% in the L group, and 15.0% in the H group, with no significant difference between the P and L or H groups.
Secondary Endpoints With Image Analysis
The angiographic restenosis rate was 32.9%, 34.9%, and 37.1% in the P, L, and H groups, respectively, with no significant differences between the P and L or H groups. The effectiveness (very effective plus effective) for prevention of thrombus formation was 13.9%, 12.9%, and 19.4% in the P, L, and H groups, respectively, (P vs L: P= 0.664, P vs H: P=0.028; Table 3) . Table 4 shows the incidence of bleeding complications. The incidence of bleeding complications (minor or major) increased dose-dependently, with a significant difference between the P and H groups (Study #01: P=0.010; Study #02: P=0.020). Major bleeding occurred in 2 cases (2.5%) in the H group in Study #01 and in 1 case (0.4%) each in the P and H groups in Study #02, without any significant difference among the groups. There was no major bleeding in the L group.
Safety Endpoint
The incidence of thrombocytopenia, defined as ≥25% decrease from baseline count and platelet count <100,000/mm 3 , was 1.4% in the P group, 8.8% in the L group, and 10.4% in the H group (P=0.035) in Study #01; and 1.7% in the P group, 6.6% in the L group (P=0.010), and 8.3% in the H group (P=0.001) in Study #02 ( Table 5 ). The incidence increased dose-dependently, and there was a significant difference between the placebo and active treatment groups. As for the incidence of thrombocytopenia with ≥25% decrease from baseline count and platelet count <50,000/mm 3 , only 1 case (1.5%) in the L group and 4 cases (5.2%) in the H group in Study #01, and 2 (0.8%) each in the L and H groups in Study #02 were reported, with no significant difference among the groups.
Exploratory Analysis
The cumulative incidence rate of post-PCI coronary events observed during 7 days after PCI (Table 2) was 3.3%, 1.3%, 2.2%, and 1.7% in the P, L, H, and abciximab (L plus H) groups, respectively. Although no significant difference was observed between the P and L or H or abciximab groups, event reduction rate during this period in the abcix- imab group was 48.5%.
Discussion
Primary Efficacy Endpoint
The present study was the first large-scale clinical trial to be conducted in Japan to investigate the efficacy and safety of abciximab for prevention of post-PCI coronary events. A number of clinical trials [8] [9] [10] [11] [16] [17] [18] [19] have revealed positive effects of GPIIb/IIIa inhibitors in patients with acute coronary syndromes undergoing PCI, and the outcomes of the present study are different from those obtained in countries other than Japan.
At the time of this study, designed with a target of 300 patients in each group, the expected incidence of postoperative events in the P group was 15%, and that in the H group was 7.5%, based on data from the EPIC trial. 8 Because the actual incidence of coronary events was much lower than expected, the statistical power was considered insufficient for verification of the efficacy of abciximab. In this study, patients with acute MI accounted for approximately 75% of the study patients, and only 2 patients died (0.21%), suggesting that most of the recruited patients had relatively mild disease. Thus, it is considered that these patients did not represent the patient population requiring treatment with abciximab, because elderly patients (≥75 years of age in Study #02) and patients with 3-vessel disease and cardiogenic shock, which are known risk factors for postoperative coronary events, [1] [2] [3] [4] 20 were excluded. Further research is required to identify the patient population actually requiring treatment with abciximab, and clinical trials with this population should be performed in order to evaluate the efficacy of abciximab in Japan.
In the EPIC trial, 8 conducted in the era of plain old balloon angioplasty (POBA), bailout stent implantation was regarded as a post-PCI event and in their incidence of stent implantation was 1.7%, 0.6%, and 0.6% in the P, lowdose (0.25 mg/kg bolus), and high-dose (0.25 mg/kg bolus followed by 12-h drip infusion) group, respectively. In contrast, in the present study, conducted during the transition from the POBA era to the stent era, bailout stent implantation was performed in approximately 25% of patients and was not considered to be a post-PCI coronary event. It is thought that bailout stent implantation can prevent reocclusion and potentially reduce the incidence of post-PCI coronary events. 21, 22 Thus, there is a possibility that the conceptual difference in coronary stenting, because of changes in the standard of care treatment, contributed to the reduced overall incidence of post-PCI coronary events and affected the results of this study.
It has been suggested that Asians may have different prognoses for acute coronary syndrome, thrombogenicity and bleeding tendency compared with Caucasians. Nakamura et al 23 reported prognoses following an acute coronary event in Japanese and North American patients who were prospectively enrolled in a multicenter study. Their results indicated a more favorable outcome in Japanese patients than in North American patients, even after adjusting for differences in clinical variables. The stent thrombosis rate in Japanese patients 24 was much lower than that reported in Western patients, 25, 26 and stent thrombosis is known to be related to platelet activation and aggregation. 27 The CRUSADE study 28 Although in-hospital mortality and reinfarction rates were similar between groups, rates of major bleeding (13.4% vs 9.4%, P<0.0001) and red blood cell transfusion (9.6% vs 6.6%, P=0.0005) were significantly higher in the Asian population, which suggests that Asians, including Japanese, have an ethnic variability in antithrombotic susceptibility and that may have affected the results of the present study.
Secondary Endpoints With Image Analysis
In the present study, the angiographic findings indicated that the effectiveness against thrombus formation was 13.9% and 19.4% in the P and H groups, respectively, with a statistically significant difference (P=0.028). Regarding the effects of abciximab on thrombus formation during the first 10 min after administration, Gold et al reported that coronary flow increased by at least 1 TIMI grade in 85% and reached TIMI grade 2 or 3 in 54% in patients with acute MI. 29 A study of abciximab used with thrombolytic agents for thrombolysis has also reported that the proportion of patients who achieved TIMI grade 3 flow at 60-90 min after the start of treatment was significantly greater in the group receiving abciximab than in the group not receiving abciximab. 30 Those findings, together with our results, suggest that abciximab can separate and break down thrombi.
Safety Evaluation
The incidences of hemorrhagic complications and thrombocytopenia were higher in the abciximab-treated groups than in the placebo group. In Study #02, the protocol was changed to prevent hemorrhagic complications and serious thrombocytopenia (eg, by establishing the upper age limit, adding and modifying exclusion criteria, adjusting the dose for intravenous drip infusion according to body weight, and reducing the initial dose of heparin). It was strongly suggested that these changes in the study design would significantly decrease the incidences of hemorrhagic events and serious thrombocytopenia associated with abciximab. In Studies #01 and #02, the incidences of minor and major bleeding tended to increase dose-dependently. Although significant differences were found between the P and H groups, no significant difference was found between the P and L groups. In addition, there was no major bleeding in the L group. Therefore, we consider that for Japanese patients the low-dose abciximab regimen is safer than the high-dose regimen.
Exploratory Analysis
Because the effect of abciximab appears most clearly during the 7-day postoperative period, 8, 9 we analyzed the incidence of coronary events during the 7 days after PCI. Although no significant difference was observed, the events reduction rate of 48.5% in the abciximab-treated group during this period was similar to that observed in large-scale foreign clinical trials (EPIC trial: 8 32.8%; EPILOG trial: 9 55.2%), suggesting the efficacy of abciximab in preventing post-PCI coronary events in Japanese patients.
Study Limitations
The timeliness in publication of the study results requires mention. In the 8 years since the enrollment and follow-up of patients was completed for the present study, progress had been made in the fields of interventional cardiology and antithrombotic treatment, and so the outcomes of this study may no longer reflect current clinical practice. However, the International Committee of Medical Journal Editors (ICMJE) states the importance of publicizing negative data from randomized clinical trials. 31 ICMJE also emphasizes that trials should be registered at the time they are set up. The present trial was designed and started before the registration system was established. Although the results are inconclusive and lack timeliness, this study has been the only clinical trial of abciximab in Japanese patients.
Conclusion
Administration of abciximab in Japanese patients with acute coronary syndrome undergoing PCI had no efficacy in reducing major coronary events, with a significant increase in both bleeding and thrombocytopenia.
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